Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label

Why did Paramount and Skydance merge? How is Trump influencing US-EU trade talks? What caused Allianz Life's data breach? Why is Toyota now America's No. 2 carmaker? How are Trump tariffs impacting US businesses? What effects will Intel's layoffs have? Why is Tesla delaying robotaxi launches?

Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label

benzinga.com/analyst-stock-ratings/downgrades/25/07/46584818/elevidys-halt-sparks-analyst-downgrades-sarepta-races-to-revise-label

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.
This reversal follows Sarepta’s initial refusal to halt distribution despite a Food and…

This story appeared on benzinga.com, 2025-07-23 19:16:44.